title: ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis.
abstract: BACKGROUND
  The diagnosis of atopic dermatitis (AD) is made using evaluated clinical criteria. Management of AD must consider the symptomatic variability of the disease.
  
  
  METHODS
  EADV eczema task force developed its guideline for atopic dermatitis diagnosis and treatment based on literature review and repeated consenting group discussions.
  
  
  CONCLUSIONS
  Basic therapy relies on hydrating topical treatment and avoidance of specific and unspecific provocation factors. Anti-inflammatory treatment based on topical glucocorticosteroids and topical calcineurin antagonists is used for exacerbation management and more recently for proactive therapy in selected cases. Topical corticosteroids remain the mainstay of therapy, but the topical calcineurin inhibitors, tacrolimus and pimecrolimus are preferred in certain locations. Systemic anti-inflammatory treatment is an option for severe refractory cases. Microbial colonization and superinfection may induce disease exacerbation and can justify additional antimicrobial/antiseptic treatment. Systemic antihistamines (H1) can relieve pruritus, but do not have sufficient effect on eczema. Adjuvant therapy includes UV irradiation preferably of UVA1 wavelength or UVB 311 nm. Dietary recommendations should be specific and given only in diagnosed individual food allergy. Allergen-specific immunotherapy to aeroallergens may be useful in selected cases. Stress-induced exacerbations may make psychosomatic counselling recommendable. 'Eczema school' educational programmes have been proven to be helpful.
authors.affiliation: Department of Dermatology and Allergy Biederstein, Technische Universität München. ulf.darsow@lrz.tum.de
authors.forename: U
authors.initials: U
authors.lastname: Darsow
authors.forename: A
authors.initials: A
authors.lastname: Wollenberg
authors.forename: D
authors.initials: D
authors.lastname: Simon
authors.forename: A
authors.initials: A
authors.lastname: Taïeb
authors.forename: T
authors.initials: T
authors.lastname: Werfel
authors.forename: A
authors.initials: A
authors.lastname: Oranje
authors.forename: C
authors.initials: C
authors.lastname: Gelmetti
authors.forename: A
authors.initials: A
authors.lastname: Svensson
authors.forename: M
authors.initials: M
authors.lastname: Deleuran
authors.forename: A-M
authors.initials: AM
authors.lastname: Calza
authors.forename: F
authors.initials: F
authors.lastname: Giusti
authors.forename: J
authors.initials: J
authors.lastname: Lübbe
authors.forename: S
authors.initials: S
authors.lastname: Seidenari
authors.forename: J
authors.initials: J
authors.lastname: Ring
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003876:Dermatitis, Atopic / Q000175:diagnosis* / Q000628:therapy*; D003879:Dermatologic Agents / Q000627:therapeutic use; D003880:Dermatology; D003937:Diagnosis, Differential; D004485:Eczema / Q000175:diagnosis* / Q000628:therapy*; D006633:Histamine Antagonists / Q000627:therapeutic use; D006801:Humans; D010506:Periodicals as Topic; D010789:Phototherapy / Q000379:methods; D017410:Practice Guidelines as Topic / Q000592:standards*
chemical_list: D000900:Anti-Bacterial Agents; D003879:Dermatologic Agents; D006633:Histamine Antagonists